Clearmind Medicine Inc. has announced a 1-for-40 reverse share split of its common shares, effective December 15, 2025. This move aims to help the company regain compliance with Nasdaq's minimum bid price requirement. After the reverse split, the number of outstanding common shares will be reduced from approximately 60 million to about 1.5 million, with fractional shares rounded up to the nearest whole share. The company's authorized share capital remains unchanged.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9600086-en) on December 10, 2025, and is solely responsible for the information contained therein.
Comments